BiotechTube
Minakem

Minakem

Louvain-la-Neuve, Belgium· Est.
minakem.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $170M

Overview

Minakem is a specialized Contract Development and Manufacturing Organization (CDMO) focused on API manufacturing and custom chemical development for the pharmaceutical industry. Founded in 2005, it leverages over 60 years of legacy expertise to offer a broad portfolio of generic and custom APIs, supported by strong regulatory capabilities including DMF filings and successful FDA inspections. The company operates as a key manufacturing partner for pharmaceutical companies, emphasizing quality, compliance, and long-term supply relationships across human and animal health markets.

OncologyCardiovascularUrologyAnesthesiologyRespiratoryEndocrinologyAnimal Health

Technology Platform

Specialized platform for the development and cGMP manufacturing of small molecule Active Pharmaceutical Ingredients (APIs) and High-Potency APIs (HPAPIs). Integrates chemical synthesis, process scale-up, analytical development, and a focus on sustainable process innovation.

Funding History

2
Total raised:$170M
Series D$120M
Debt$50M

Opportunities

The growing trend of pharmaceutical companies outsourcing API manufacturing to specialized CDMOs presents a major growth opportunity.
Expansion of its DMF-held generic API portfolio allows Minakem to capture market share in the generics sector.
The increasing demand for complex and high-potency APIs, particularly in oncology, offers high-value contracts for companies with the requisite technical and containment expertise.

Risk Factors

Operational risks include potential quality control failures, regulatory non-compliance at its manufacturing sites, or supply chain disruptions, which could severely impact client trust and revenue.
The company faces intense competition in the global CDMO market, requiring continuous investment in technology and cost competitiveness.
Its business is also indirectly dependent on the clinical and commercial success of its clients' drug candidates.

Competitive Landscape

Minakem competes in a global and fragmented CDMO market against large players like Lonza, Catalent, and Siegfried, as well as numerous specialized API manufacturers. Its differentiation is based on its deep expertise in complex small molecule and HPAPI chemistry, a strong regulatory track record, and a strategic focus as a dedicated API partner rather than a full-service CDMO. Competition is based on technical capability, quality, reliability, cost, and geographic location.

More companies in Small Molecule Drugs →More companies in Belgium →